Investigating the Optimal Management of Dolutegravir Resistance

RecruitingOBSERVATIONAL
Enrollment

6,600

Participants

Timeline

Start Date

March 3, 2025

Primary Completion Date

October 31, 2026

Study Completion Date

October 31, 2026

Conditions
HIV-1-infection
Interventions
DRUG

Continue DTG-based antiretroviral therapy

Participants will continue on DTG-based ART after enrollment for up to 12 months

BEHAVIORAL

Enhanced adherence counselling

Participants with VL ≥200 copies/mL will undergo enhanced adherence counselling

Trial Locations (9)

Unknown

RECRUITING

Jaramogi Oginga Odinga Teaching and Referral Hospital, Kisumu

NOT_YET_RECRUITING

Bomu Hospital, Mombasa

RECRUITING

Butha-Buthe District Hospital, Butha-Buthe

RECRUITING

Mokhotlong District Hospital, Mokhotlong

NOT_YET_RECRUITING

CS Ponta Gea, Beira

NOT_YET_RECRUITING

CS Machava II, Maputo

NOT_YET_RECRUITING

CS Ndlavela, Maputo

NOT_YET_RECRUITING

MUHAS Clinical Trial Unit, Dar es Salaam

00100

RECRUITING

Kenyatta National Hospital, Nairobi

All Listed Sponsors
collaborator

Instituto Nacional de Saúde, Mozambique

OTHER_GOV

collaborator

Muhimbili University of Health and Allied Sciences

OTHER

collaborator

SolidarMed

OTHER

collaborator

London School of Hygiene and Tropical Medicine

OTHER

lead

University of Nairobi

OTHER